Corline Biomedical AB (STO:CLBIO)
Sweden flag Sweden · Delayed Price · Currency is SEK
15.65
-0.25 (-1.57%)
Mar 9, 2026, 5:29 PM CET

Corline Biomedical AB Company Description

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden.

The company’s products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting.

Its products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries.

The company also provides medical devices, such as coated stents and coated ablation catheter. Corline Biomedical AB was incorporated in 1991 and is based in Uppsala, Sweden.

Corline Biomedical AB
Country Sweden
Founded 1991
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Henrik Nittmar

Contact Details

Address:
Lefflersgatan 5
Uppsala, 754 50
Sweden
Phone 46 18 71 30 90
Website corline.se

Stock Details

Ticker Symbol CLBIO
Exchange Nasdaq Stockholm
Fiscal Year January - December
Reporting Currency SEK
ISIN Number SE0006887451
SIC Code 2836

Key Executives

Name Position
Dr. Henrik Nittmar Ph.D. Chief Executive Officer
Asa Holm Chief Operating Officer